Board meeting on 27 Oct 2026 to approve Q2 and H1 FY26 results

EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.1%Reaction day

₹233.45

prior close

₹234.35

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+3.7% vs market

Pharmaceuticals peers, median of 172sector-0.6%+2.7% vs sector

On the reaction day the stock moved 3.7 pts more than Nifty Microcap 250 and 2.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.8

15m

-1.0

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.1-1.6+3.7-0.6+2.7

Next day

+4.6-1.0+5.5-0.7+5.3

+1.0-2.6+3.7-1.9+3.0

-2.0-5.1+3.2-3.5+1.6

-3.5-6.1+2.6-4.4+0.9

-1.0-8.3+7.2-6.1+5.0

-6.1-6.4+0.3-2.8-3.3

15d

-7.9pendingpending-0.9-7.0

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indoco Remedies has informed stock exchanges that its Board of Directors will meet on Tuesday, 27 October 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. The company also confirmed that the trading window for designated persons and their immediate relatives will remain closed until 29 October 2026, which is 48 hours after the results declaration.

Likely market impact

Routine board meeting intimation under SEBI norms. Investors should watch for Q2 and H1 FY26 results announcement around 27 October 2026.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹520.2 Cr	₹484.7 Cr	+7.3%
Operating profit	−₹14.92 Cr	−₹13.76 Cr	loss widened
Profit after tax	₹19.47 Cr	−₹9.21 Cr	turned positive
EBITDA margin	16.1%	8.8%	+7.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.